<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294630</url>
  </required_header>
  <id_info>
    <org_study_id>1206011023</org_study_id>
    <secondary_id>1R01FD004793-01A1</secondary_id>
    <secondary_id>FD004793</secondary_id>
    <nct_id>NCT02294630</nct_id>
  </id_info>
  <brief_title>Aerosolized Surfactant in Neonatal RDS</brief_title>
  <acronym>AS-02</acronym>
  <official_title>Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sood, Beena G., MD, MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sood, Beena G., MD, MS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of&#xD;
      mortality and morbidity in preterm infants. Intratracheal instillation, the only approved&#xD;
      means of surfactant delivery, requires endotracheal intubation and mechanical ventilation&#xD;
      with their attendant risks. Interventions that decrease need for intubation and mechanical&#xD;
      ventilation like noninvasive ventilation (NIV) including nasal continuous positive airway&#xD;
      pressure, high flow nasal cannula or nasal intermittent mandatory ventilation are&#xD;
      increasingly being used for initial respiratory support in preterm neonates with RDS to&#xD;
      improve outcomes. Aerosolized surfactant delivered during NIV is an innovative and promising&#xD;
      concept for the treatment of RDS - retaining the advantages of early surfactant with alveolar&#xD;
      recruitment while obviating the risks of intubation and mechanical ventilation. The&#xD;
      investigators overall hypothesis is that treatment of RDS with aerosolized surfactant in&#xD;
      preterm infants undergoing NIV is safe and feasible and will result in short-term improvement&#xD;
      in oxygenation and ventilation. The objective of this proposal is to perform a single-center&#xD;
      unblinded Phase II randomized clinical trial of aerosolized surfactant for the treatment of&#xD;
      RDS in preterm neonates undergoing NIV. Funding Source - FDA-OOPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Feasibility</measure>
    <time_frame>During and within 6 hours after end of study drug administration, expected maximum of approximately 14 hours</time_frame>
    <description>Since surfactant reflux is typically considered to be one of the most likely adverse events associated with the intervention, it was planned to report the number of participants specifically with surfactant reflux for this Outcome Measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Status as Evaluated by Dose Level</measure>
    <time_frame>During study drug administration, expected maximum of approximately 8 hours for adverse effects and infant comfort; need for intubation was assessed within 72 hours of study intervention.</time_frame>
    <description>Optimal dosing schedule was determined by preliminary evidence of efficacy (Need for intubation within 72 hours), lack of adverse effects, and overall infant comfort as assessed by bedside clinical caregivers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Term Efficacy as Assessed by Need for Intubation</measure>
    <time_frame>Within 72 hours of study intervention</time_frame>
    <description>It will be suggested that infants be intubated and receive MV if they met 2 or more of 5 failure criteria: i). worsening clinical signs of respiratory distress (increasing tachypnea; expiratory grunting; intercostal, subcostal, and/or sternal recession); ii). apnea treated with positive pressure ventilation (PPV) by mask on 2 or more occasions in 1 hour; iii). FIO2 &gt;0.5 to maintain pulse oxygen saturations 90%-95% for &gt;30 minutes; iv). pH &lt;7.2 on 2 arterial or capillary blood gases taken &gt;30 minutes apart; and v). partial pressure of CO2 (PCO2) of &gt;65 mm Hg on 2 CBG/ABGs taken 30 minutes apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Parameters - pH</measure>
    <time_frame>60±30 minutes after end of study intervention</time_frame>
    <description>Blood gas pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gas Parameters - pCO2</measure>
    <time_frame>60±30 minutes after end of study intervention</time_frame>
    <description>Blood gas pCO2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Oximetry</measure>
    <time_frame>60±30 minutes after end of study intervention</time_frame>
    <description>Transcutaneous Pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Heart Rate</measure>
    <time_frame>60±30 minutes after end of study intervention</time_frame>
    <description>Vital signs included heart rate, respiratory rate and systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Respiratory Rate</measure>
    <time_frame>60±30 minutes after end of study intervention</time_frame>
    <description>Vital signs included heart rate, respiratory rate and systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Systolic Blood Pressure</measure>
    <time_frame>60±30 minutes after end of study intervention</time_frame>
    <description>Systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses of Surfactant - Aerosolized &amp; Intratracheal</measure>
    <time_frame>Within 72 hours of study intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumothorax, Pneumomediastinum or Other Air Leak</measure>
    <time_frame>Within 72 hours of study intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cerebral Oxygenation From Baseline as Evaluated at End of Study Intervention</measure>
    <time_frame>During and within 6 hours after end of study intervention, expected maximum of approximately 14 hours</time_frame>
    <description>Changes in cerebral oxygenation from baseline as evaluated at end of study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Surfactant Activity in Gastric Aspirates</measure>
    <time_frame>During study intervention, expected maximum of approximately 8 hours</time_frame>
    <description>Concentration of major surfactant lipid (PC 16:0/16:0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Duration of Non-invasive and Invasive Ventilation</measure>
    <time_frame>at discharge</time_frame>
    <description>Cumulative duration of non-invasive and invasive ventilation at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen, Intensive Care, Hospital Stay</measure>
    <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
    <description>Duration of supplemental oxygen, and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at Start of Feeds, Feeding Progression, Age at Full Enteral Feeds</measure>
    <time_frame>During initial hospital stay, expected 1st 2 weeks of life</time_frame>
    <description>Age at start of feeds, and age at full enteral feeds presented in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Blood Transfusions</measure>
    <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
    <description>Number of infants requiring blood transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Parameters</measure>
    <time_frame>At 7 days, 28 days, 36 weeks corrected GA and discharge</time_frame>
    <description>Weight at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidities Associated With Prematurity</measure>
    <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
    <description>Grade III &amp; IV IVH PDA requiring ligation ROP treated with Laser Surgical NEC BPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to Hospital Discharge</measure>
    <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
    <description>Survival to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to Discharge Without Severe Morbidity</measure>
    <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
    <description>Survival to discharge without severe BPD, severe IVH, surgical NEC or ROP treated with Laser</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>Dose Schedule I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Schedule II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Schedule III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Schedule IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfactant</intervention_name>
    <description>Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
    <arm_group_label>Dose Schedule I</arm_group_label>
    <arm_group_label>Dose Schedule II</arm_group_label>
    <arm_group_label>Dose Schedule III</arm_group_label>
    <arm_group_label>Dose Schedule IV</arm_group_label>
    <other_name>Survanta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infants admitted to the NICU at Hutzel Women's Hospital (HWH)/Children's Hospital of&#xD;
             Michigan (CHM)&#xD;
&#xD;
          2. Gestational age of 240/7-366/7 weeks&#xD;
&#xD;
          3. Postnatal age ≤ 24 hours&#xD;
&#xD;
          4. Clinical diagnosis of RDS based on (i) presence of at least two of the four classic&#xD;
             symptoms (need of supplemental oxygen, tachypnea, intercostal retractions or&#xD;
             grunting), and (ii) exclusion of other causes of respiratory failure and (iii)&#xD;
             Clinician intent to administer surfactant if infant requires intubation&#xD;
&#xD;
          5. Respiratory support with NIV (CPAP or NIPPV or HFNC) with FiO2 ≥25% or PEEP ≥ 4 cmH20&#xD;
             or HFNC rate ≥ 2 LPM for ≤8 hours&#xD;
&#xD;
          6. Written informed consent from parent/guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous receipt of surfactant&#xD;
&#xD;
          2. Infants with respiratory distress who are unstable and require immediate intubation&#xD;
&#xD;
          3. Active air leak syndrome (e.g. pneumothorax, pneumomediastinum)&#xD;
&#xD;
          4. Lethal congenital malformations; death anticipated within first 3 days of life;&#xD;
             decision to withhold support&#xD;
&#xD;
          5. Serious abdominal, cardiac, airway or respiratory malformations including tracheal&#xD;
             esophageal fistula, intestinal atresia, omphalocele, gastroschisis, pulmonary&#xD;
             hypoplasia, or diaphragmatic hernia&#xD;
&#xD;
          6. Neuromuscular disorder resulting in respiratory compromise&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beena G. Sood, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hutzel Women's Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sood BG, Cortez J, Kolli M, Sharma A, Delaney-Black V, Chen X. Aerosolized surfactant in neonatal respiratory distress syndrome: Phase I study. Early Hum Dev. 2019 Jul;134:19-25. doi: 10.1016/j.earlhumdev.2019.05.005. Epub 2019 May 20.</citation>
    <PMID>31121339</PMID>
  </reference>
  <results_reference>
    <citation>Sood BG, Thomas R, Delaney-Black V, Xin Y, Sharma A, Chen X. Aerosolized Beractant in neonatal respiratory distress syndrome: A randomized fixed-dose parallel-arm phase II trial. Pulm Pharmacol Ther. 2021 Feb;66:101986. doi: 10.1016/j.pupt.2020.101986. Epub 2020 Dec 16.</citation>
    <PMID>33338661</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>March 26, 2021</results_first_submitted>
  <results_first_submitted_qc>July 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2021</results_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02294630/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 159 enrolled and randomized participants, 149 met eligibility criteria and proceeded with treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Schedule I</title>
          <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="P2">
          <title>Dose Schedule II</title>
          <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="P3">
          <title>Dose Schedule III</title>
          <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="P4">
          <title>Dose Schedule IV</title>
          <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Schedule I</title>
          <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="B2">
          <title>Dose Schedule II</title>
          <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="B3">
          <title>Dose Schedule III</title>
          <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="B4">
          <title>Dose Schedule IV</title>
          <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="3.0"/>
                    <measurement group_id="B2" value="31.6" spread="3.3"/>
                    <measurement group_id="B3" value="31.0" spread="3.0"/>
                    <measurement group_id="B4" value="31.7" spread="3.2"/>
                    <measurement group_id="B5" value="31.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>GA strata</title>
              <category_list>
                <category>
                  <title>GA strata I (24-28 weeks)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GA strata II (29-32 weeks)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GA strata III (33-36 weeks)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Feasibility</title>
        <description>Since surfactant reflux is typically considered to be one of the most likely adverse events associated with the intervention, it was planned to report the number of participants specifically with surfactant reflux for this Outcome Measure</description>
        <time_frame>During and within 6 hours after end of study drug administration, expected maximum of approximately 14 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Feasibility</title>
          <description>Since surfactant reflux is typically considered to be one of the most likely adverse events associated with the intervention, it was planned to report the number of participants specifically with surfactant reflux for this Outcome Measure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Status as Evaluated by Dose Level</title>
        <description>Optimal dosing schedule was determined by preliminary evidence of efficacy (Need for intubation within 72 hours), lack of adverse effects, and overall infant comfort as assessed by bedside clinical caregivers.</description>
        <time_frame>During study drug administration, expected maximum of approximately 8 hours for adverse effects and infant comfort; need for intubation was assessed within 72 hours of study intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Status as Evaluated by Dose Level</title>
          <description>Optimal dosing schedule was determined by preliminary evidence of efficacy (Need for intubation within 72 hours), lack of adverse effects, and overall infant comfort as assessed by bedside clinical caregivers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Need for Intubation within 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events - surfactant reflux</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall infant comfort during AS as assessed by bedside nurse (infant most comfortable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short Term Efficacy as Assessed by Need for Intubation</title>
        <description>It will be suggested that infants be intubated and receive MV if they met 2 or more of 5 failure criteria: i). worsening clinical signs of respiratory distress (increasing tachypnea; expiratory grunting; intercostal, subcostal, and/or sternal recession); ii). apnea treated with positive pressure ventilation (PPV) by mask on 2 or more occasions in 1 hour; iii). FIO2 &gt;0.5 to maintain pulse oxygen saturations 90%-95% for &gt;30 minutes; iv). pH &lt;7.2 on 2 arterial or capillary blood gases taken &gt;30 minutes apart; and v). partial pressure of CO2 (PCO2) of &gt;65 mm Hg on 2 CBG/ABGs taken 30 minutes apart.</description>
        <time_frame>Within 72 hours of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Term Efficacy as Assessed by Need for Intubation</title>
          <description>It will be suggested that infants be intubated and receive MV if they met 2 or more of 5 failure criteria: i). worsening clinical signs of respiratory distress (increasing tachypnea; expiratory grunting; intercostal, subcostal, and/or sternal recession); ii). apnea treated with positive pressure ventilation (PPV) by mask on 2 or more occasions in 1 hour; iii). FIO2 &gt;0.5 to maintain pulse oxygen saturations 90%-95% for &gt;30 minutes; iv). pH &lt;7.2 on 2 arterial or capillary blood gases taken &gt;30 minutes apart; and v). partial pressure of CO2 (PCO2) of &gt;65 mm Hg on 2 CBG/ABGs taken 30 minutes apart.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Parameters - pH</title>
        <description>Blood gas pH</description>
        <time_frame>60±30 minutes after end of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Parameters - pH</title>
          <description>Blood gas pH</description>
          <units>pH units for pH, mmHg for pCO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" spread="0.05"/>
                    <measurement group_id="O2" value="7.36" spread="0.07"/>
                    <measurement group_id="O3" value="7.36" spread="0.06"/>
                    <measurement group_id="O4" value="7.35" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gas Parameters - pCO2</title>
        <description>Blood gas pCO2.</description>
        <time_frame>60±30 minutes after end of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gas Parameters - pCO2</title>
          <description>Blood gas pCO2.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="8"/>
                    <measurement group_id="O2" value="45" spread="9"/>
                    <measurement group_id="O3" value="43" spread="6"/>
                    <measurement group_id="O4" value="45" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Oximetry</title>
        <description>Transcutaneous Pulse oximetry</description>
        <time_frame>60±30 minutes after end of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Oximetry</title>
          <description>Transcutaneous Pulse oximetry</description>
          <units>percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.95" spread="3.34"/>
                    <measurement group_id="O2" value="96.95" spread="5.22"/>
                    <measurement group_id="O3" value="97.37" spread="3.16"/>
                    <measurement group_id="O4" value="97.47" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Heart Rate</title>
        <description>Vital signs included heart rate, respiratory rate and systolic blood pressure</description>
        <time_frame>60±30 minutes after end of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Heart Rate</title>
          <description>Vital signs included heart rate, respiratory rate and systolic blood pressure</description>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="12"/>
                    <measurement group_id="O2" value="142" spread="14"/>
                    <measurement group_id="O3" value="138" spread="12"/>
                    <measurement group_id="O4" value="136" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Respiratory Rate</title>
        <description>Vital signs included heart rate, respiratory rate and systolic blood pressure</description>
        <time_frame>60±30 minutes after end of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Respiratory Rate</title>
          <description>Vital signs included heart rate, respiratory rate and systolic blood pressure</description>
          <units>breaths/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="17"/>
                    <measurement group_id="O2" value="47" spread="15"/>
                    <measurement group_id="O3" value="46" spread="15"/>
                    <measurement group_id="O4" value="47" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Systolic Blood Pressure</title>
        <description>Systolic blood pressure</description>
        <time_frame>60±30 minutes after end of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Systolic Blood Pressure</title>
          <description>Systolic blood pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="9"/>
                    <measurement group_id="O2" value="51" spread="8"/>
                    <measurement group_id="O3" value="54" spread="10"/>
                    <measurement group_id="O4" value="53" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Doses of Surfactant - Aerosolized &amp; Intratracheal</title>
        <time_frame>Within 72 hours of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Doses of Surfactant - Aerosolized &amp; Intratracheal</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>One dose of aerosolized surfactant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two doses of aerosolized surfactant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of doses of intratracheal surfactant - one</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of doses of intratracheal surfactant - two</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of doses of intratracheal surfactant - three</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of doses of intratracheal surfactant - four</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumothorax, Pneumomediastinum or Other Air Leak</title>
        <time_frame>Within 72 hours of study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumothorax, Pneumomediastinum or Other Air Leak</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cerebral Oxygenation From Baseline as Evaluated at End of Study Intervention</title>
        <description>Changes in cerebral oxygenation from baseline as evaluated at end of study intervention</description>
        <time_frame>During and within 6 hours after end of study intervention, expected maximum of approximately 14 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cerebral Oxygenation From Baseline as Evaluated at End of Study Intervention</title>
          <description>Changes in cerebral oxygenation from baseline as evaluated at end of study intervention</description>
          <units>percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="8"/>
                    <measurement group_id="O2" value="80" spread="8"/>
                    <measurement group_id="O3" value="78" spread="11"/>
                    <measurement group_id="O4" value="79" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Surfactant Activity in Gastric Aspirates</title>
        <description>Concentration of major surfactant lipid (PC 16:0/16:0)</description>
        <time_frame>During study intervention, expected maximum of approximately 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Surfactant Activity in Gastric Aspirates</title>
          <description>Concentration of major surfactant lipid (PC 16:0/16:0)</description>
          <units>ng per mg of protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="14.6"/>
                    <measurement group_id="O2" value="9.5" spread="9.2"/>
                    <measurement group_id="O3" value="8.8" spread="7.8"/>
                    <measurement group_id="O4" value="8.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Duration of Non-invasive and Invasive Ventilation</title>
        <description>Cumulative duration of non-invasive and invasive ventilation at discharge</description>
        <time_frame>at discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Duration of Non-invasive and Invasive Ventilation</title>
          <description>Cumulative duration of non-invasive and invasive ventilation at discharge</description>
          <units>number of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration of NIV (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="8.1"/>
                    <measurement group_id="O2" value="7.0" spread="14.6"/>
                    <measurement group_id="O3" value="7.9" spread="14.2"/>
                    <measurement group_id="O4" value="6.1" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Invasive ventilation (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="5.1"/>
                    <measurement group_id="O2" value="0.9" spread="4.0"/>
                    <measurement group_id="O3" value="1.6" spread="5.1"/>
                    <measurement group_id="O4" value="2.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Supplemental Oxygen, Intensive Care, Hospital Stay</title>
        <description>Duration of supplemental oxygen, and hospital stay</description>
        <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Supplemental Oxygen, Intensive Care, Hospital Stay</title>
          <description>Duration of supplemental oxygen, and hospital stay</description>
          <units>number of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration of supplemental oxygen (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="18.5"/>
                    <measurement group_id="O2" value="9.0" spread="22.9"/>
                    <measurement group_id="O3" value="10.7" spread="25.2"/>
                    <measurement group_id="O4" value="8.9" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of hospital stay (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="28"/>
                    <measurement group_id="O2" value="26.4" spread="24.3"/>
                    <measurement group_id="O3" value="32.1" spread="29.9"/>
                    <measurement group_id="O4" value="28.3" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age at Start of Feeds, Feeding Progression, Age at Full Enteral Feeds</title>
        <description>Age at start of feeds, and age at full enteral feeds presented in days</description>
        <time_frame>During initial hospital stay, expected 1st 2 weeks of life</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Age at Start of Feeds, Feeding Progression, Age at Full Enteral Feeds</title>
          <description>Age at start of feeds, and age at full enteral feeds presented in days</description>
          <units>age in days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age at start of feeds (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread=".7"/>
                    <measurement group_id="O2" value="1.6" spread="1.7"/>
                    <measurement group_id="O3" value="1.8" spread="1.7"/>
                    <measurement group_id="O4" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at full enteral feeds (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="8.8"/>
                    <measurement group_id="O2" value="7.8" spread="7.3"/>
                    <measurement group_id="O3" value="11.8" spread="11.7"/>
                    <measurement group_id="O4" value="12.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Blood Transfusions</title>
        <description>Number of infants requiring blood transfusions</description>
        <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Blood Transfusions</title>
          <description>Number of infants requiring blood transfusions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Parameters</title>
        <description>Weight at discharge</description>
        <time_frame>At 7 days, 28 days, 36 weeks corrected GA and discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Parameters</title>
          <description>Weight at discharge</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2153" spread="458"/>
                    <measurement group_id="O2" value="2222" spread="431"/>
                    <measurement group_id="O3" value="2235" spread="561"/>
                    <measurement group_id="O4" value="2281" spread="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morbidities Associated With Prematurity</title>
        <description>Grade III &amp; IV IVH PDA requiring ligation ROP treated with Laser Surgical NEC BPD</description>
        <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidities Associated With Prematurity</title>
          <description>Grade III &amp; IV IVH PDA requiring ligation ROP treated with Laser Surgical NEC BPD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade III &amp; IV IVH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDA requiring ligation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP treated with Laser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical NEC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival to Hospital Discharge</title>
        <description>Survival to hospital discharge</description>
        <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival to Hospital Discharge</title>
          <description>Survival to hospital discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival to Discharge Without Severe Morbidity</title>
        <description>Survival to discharge without severe BPD, severe IVH, surgical NEC or ROP treated with Laser</description>
        <time_frame>During initial hospital stay, expected &lt;= 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Schedule I</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O2">
            <title>Dose Schedule II</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O3">
            <title>Dose Schedule III</title>
            <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
          <group group_id="O4">
            <title>Dose Schedule IV</title>
            <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival to Discharge Without Severe Morbidity</title>
          <description>Survival to discharge without severe BPD, severe IVH, surgical NEC or ROP treated with Laser</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During and within 6 hours after the end of study drug administration, an expected maximum of approximately 14 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Schedule I</title>
          <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="E2">
          <title>Dose Schedule II</title>
          <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="E3">
          <title>Dose Schedule III</title>
          <description>Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
        <group group_id="E4">
          <title>Dose Schedule IV</title>
          <description>Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.&#xD;
Surfactant: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Surfactant reflux from nose/mouth</sub_title>
                <description>Surfactant reflux from nose/mouth</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Desaturations</sub_title>
                <description>Desaturations</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Plugging of nasal prongs</sub_title>
                <description>Plugging of nasal prongs</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Increased secretions requiring suctioning</sub_title>
                <description>Increased secretions requiring suctioning</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Residual surfactant in nasal prongs</sub_title>
                <description>Residual surfactant in nasal prongs</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dislodged prongs</sub_title>
                <description>Dislodged prongs</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beena G. Sood, MD, MS</name_or_title>
      <organization>Wayne State University</organization>
      <phone>313-745-5638</phone>
      <email>bsood@med.wayne.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

